Daratumumab approved in combo with VTd for transplant-eligible multiple myelomaSeptember 26, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Subcutaneous and IV daratumumab combos appear comparable in myelomaSeptember 26, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Quadruplet prolongs progression-free survival in newly diagnosed myelomaSeptember 26, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Oral triplet shows promise for relapsed/refractory myelomaSeptember 22, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Combo could be new standard for transplant-eligible, newly diagnosed myeloma patientsSeptember 20, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Adding elotuzumab to lenalidomide/dexamethasone can prolong survival in relapsed/refractory myelomaSeptember 19, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
CT103A elicits responses after prior CAR T-cell relapseSeptember 19, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Melflufen-dexamethasone active in patients with relapsed/refractory myeloma and EMDSeptember 19, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
VRD pretransplant induction deepens responses in myelomaSeptember 17, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersTransplantation
Progressive myeloma after induction? Go straight to transplantSeptember 6, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersTransplantation
Combo produces responses in triple-class refractory myelomaAugust 21, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
SC daratumumab deemed feasible for every multiple myeloma patientJuly 11, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Daratumumab wins new indication for newly diagnosed myeloma patientsJune 28, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Triplet offers longest PFS yet seen in relapsed/refractory myelomaJune 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Four-drug combo bests triplet in newly diagnosed myelomaJune 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
